MedTrace Logo

Subconjunctival Bevacizumab and Recurrent Pterygium

NCT01744756 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-12-07

No results posted yet for this study

Summary

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Conditions

  • Recurrent Pterygium

Interventions

DRUG

Bevacizumab

One subconjunctival aplication of Bevacizumabe 0,5ml

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Principal Investigators

  • Larissa S Stival, MD · Instituto de Olhos de Goiania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-07-31
Completion
2012-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01744756 on ClinicalTrials.gov